Sesen Bio (FRA:PCBK) Growth Rank : 0 (As of Jun. 21, 2024)

View and export this data going back to 2016. Start your Free Trial

What is Sesen Bio Growth Rank?

Sesen Bio has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Sesen Bio Growth Rank Related Terms

Thank you for viewing the detailed overview of Sesen Bio's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Sesen Bio (FRA:PCBK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sesen Bio Inc (FRA:PCBK) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

245 First Street, Suite 1800, Cambridge, MA, USA, 02142

Website

https://www.sesenbio.com

Sesen Bio Inc is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The company's product candidate, Vicineum, also known as VB4-845, is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG.

Sesen Bio (FRA:PCBK) Headlines

From GuruFocus

Pacific Continental Corp. Reports Operating Results (10-Q)

By gurufocus 10qk • 11-04-2009

Pacific Continental Corp. (PCBK) President/COO Roger S Busse buys 1,000 Shares

By GuruFocus Research GuruFocus Editor • 10-15-2009

Pacific Continental Corp. (PCBK) CEO Hal Brown buys 5,000 Shares

By GuruFocus Research GuruFocus Editor • 10-15-2009

Pacific Continental Corp. (PCBK) CFO Michael Reynolds sells 1,650 Shares

By GuruFocus Research GuruFocus Editor • 02-22-2010